AR055009A1 - Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento - Google Patents
Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamentoInfo
- Publication number
- AR055009A1 AR055009A1 ARP050105271A ARP050105271A AR055009A1 AR 055009 A1 AR055009 A1 AR 055009A1 AR P050105271 A ARP050105271 A AR P050105271A AR P050105271 A ARP050105271 A AR P050105271A AR 055009 A1 AR055009 A1 AR 055009A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- manufacture
- pharmaceutical composition
- gemcitabine
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229960005277 gemcitabine Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000670727 Amida Species 0.000 title 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 4
- 239000013078 crystal Substances 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 gemcitabine amide Chemical class 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Un compuesto profármaco de amida de gemcitabina que es 1-(2,2-dilfluoro-2-desoxi-beta-D-ribofuranosil)-4-(2-propil-1-oxopentil) aminopirimidin-2-ona de la formula (1), el compuesto puede estar en la forma de un co-cristal del ácido p-toluensulfonico o un co-cristal hidrato del ácido p-toluensulfonico. Composicion farmacéutica que comprende al compuesto junto con un excipiente farmacéuticamente aceptables. Uso del compuesto para la manufactura de un medicamento para el tratamiento de neoplasmas susceptibles, tales como linfoma de células T, sarcoma de tejido liso, cáncer pancreático, cáncer ce mama, linfoma de Hodgkin, linfoma no de Hodgkin, cáncer de pulmon de células no pequenas, cáncer de ovario y cáncer de vejiga.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63742204P | 2004-12-17 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055009A1 true AR055009A1 (es) | 2007-08-01 |
Family
ID=36168678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105271A AR055009A1 (es) | 2004-12-17 | 2005-12-15 | Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7691827B2 (es) |
| EP (1) | EP1831237B1 (es) |
| JP (1) | JP5022911B2 (es) |
| KR (1) | KR100874052B1 (es) |
| CN (1) | CN101080417B (es) |
| AR (1) | AR055009A1 (es) |
| AT (1) | ATE405573T1 (es) |
| AU (1) | AU2005316922B2 (es) |
| BR (1) | BRPI0519117A2 (es) |
| CA (1) | CA2589850C (es) |
| CY (1) | CY1108447T1 (es) |
| DE (1) | DE602005009255D1 (es) |
| DK (1) | DK1831237T3 (es) |
| EA (1) | EA011868B1 (es) |
| ES (1) | ES2310860T3 (es) |
| HR (1) | HRP20080529T3 (es) |
| IL (1) | IL183666A (es) |
| MA (1) | MA29154B1 (es) |
| MX (1) | MX2007007228A (es) |
| MY (1) | MY143677A (es) |
| NO (1) | NO20073368L (es) |
| NZ (1) | NZ554732A (es) |
| PE (1) | PE20060771A1 (es) |
| PL (1) | PL1831237T3 (es) |
| PT (1) | PT1831237E (es) |
| RS (1) | RS50629B (es) |
| SI (1) | SI1831237T1 (es) |
| TW (1) | TWI326687B (es) |
| UA (1) | UA86119C2 (es) |
| WO (1) | WO2006065525A1 (es) |
| ZA (1) | ZA200705019B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007149891A2 (en) * | 2006-06-21 | 2007-12-27 | Eli Lilly And Company | Crystalline forms of gemcitabine amide prodrug, compositions and use thereof |
| TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| CN101525361B (zh) * | 2009-04-21 | 2010-11-17 | 济南圣鲁金药物技术开发有限公司 | 基于吉西他滨结构的前药及其合成方法及应用 |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CN102432654A (zh) * | 2011-09-26 | 2012-05-02 | 宋云龙 | 吉西他滨酰胺衍生物及其制备方法和用途 |
| CA2890359A1 (en) | 2012-11-07 | 2014-05-15 | Zucai SUO | Substituted gemcitabine aryl amide analogs and treatment methods using same |
| BR112015010941A2 (pt) | 2012-11-13 | 2017-07-11 | Boyen Therapeutics Inc | pró-fármacos de gemcitabina e suas utilizações |
| US10059733B2 (en) | 2014-03-03 | 2018-08-28 | Nucorion Pharmaceuticals, Inc. | Gemcitabine analogs |
| WO2016078160A1 (zh) * | 2014-11-17 | 2016-05-26 | 常州方圆制药有限公司 | 胞苷衍生物及其应用 |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| CA3088287A1 (en) | 2018-01-10 | 2019-07-18 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| EA202091856A1 (ru) | 2018-02-02 | 2020-12-07 | Маверикс Онколоджи, Инк. | Низкомолекулярные лекарственные коньюгаты гемцитабина монофосфата |
| AU2019258590B2 (en) | 2018-04-26 | 2022-09-08 | NanoMed Holdings Pty Ltd | Gemcitabine amphiphile prodrugs |
| CN108864250A (zh) * | 2018-05-29 | 2018-11-23 | 北京大学 | 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用 |
| MX2021000740A (es) * | 2018-08-03 | 2021-03-26 | Cellix Bio Private Ltd | Composiciones y metodos para el tratamiento del cancer. |
| AU2020315394A1 (en) | 2019-07-17 | 2022-02-17 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
| EP4143199B1 (en) | 2020-04-21 | 2025-11-19 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| PL442924A1 (pl) * | 2022-11-23 | 2024-05-27 | Politechnika Śląska | Prolek - glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| US4965374A (en) * | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| RU2131880C1 (ru) * | 1992-06-22 | 1999-06-20 | Эли Лилли Энд Компани | Способ получения обогащенных бета-аномером нуклеозидов |
| YU43193A (sh) * | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
| KR100483256B1 (ko) | 1997-01-24 | 2005-04-15 | 콘파마 아에스 | 젬시타빈 유도체 |
| GB2321454A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Gemcitabine esters and amides |
| US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| US6624142B2 (en) * | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US6376470B1 (en) * | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
| AU2003291726A1 (en) * | 2002-11-04 | 2004-06-07 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| US7846436B2 (en) * | 2003-11-28 | 2010-12-07 | Chemgenes Corporation | Oligonucleotides and related compounds |
-
2005
- 2005-11-30 WO PCT/US2005/043125 patent/WO2006065525A1/en not_active Ceased
- 2005-11-30 US US11/719,705 patent/US7691827B2/en not_active Expired - Fee Related
- 2005-11-30 CA CA2589850A patent/CA2589850C/en not_active Expired - Fee Related
- 2005-11-30 CN CN2005800431815A patent/CN101080417B/zh not_active Expired - Fee Related
- 2005-11-30 DE DE602005009255T patent/DE602005009255D1/de not_active Expired - Lifetime
- 2005-11-30 KR KR1020077013628A patent/KR100874052B1/ko not_active Expired - Fee Related
- 2005-11-30 NZ NZ554732A patent/NZ554732A/en not_active IP Right Cessation
- 2005-11-30 RS RSP-2008/0502A patent/RS50629B/sr unknown
- 2005-11-30 ES ES05852411T patent/ES2310860T3/es not_active Expired - Lifetime
- 2005-11-30 MX MX2007007228A patent/MX2007007228A/es active IP Right Grant
- 2005-11-30 UA UAA200706706A patent/UA86119C2/ru unknown
- 2005-11-30 SI SI200530455T patent/SI1831237T1/sl unknown
- 2005-11-30 PT PT05852411T patent/PT1831237E/pt unknown
- 2005-11-30 BR BRPI0519117-3A patent/BRPI0519117A2/pt not_active IP Right Cessation
- 2005-11-30 PL PL05852411T patent/PL1831237T3/pl unknown
- 2005-11-30 EA EA200701300A patent/EA011868B1/ru not_active IP Right Cessation
- 2005-11-30 JP JP2007546709A patent/JP5022911B2/ja not_active Expired - Fee Related
- 2005-11-30 EP EP05852411A patent/EP1831237B1/en not_active Expired - Lifetime
- 2005-11-30 HR HR20080529T patent/HRP20080529T3/xx unknown
- 2005-11-30 AU AU2005316922A patent/AU2005316922B2/en not_active Ceased
- 2005-11-30 AT AT05852411T patent/ATE405573T1/de active
- 2005-11-30 DK DK05852411T patent/DK1831237T3/da active
- 2005-12-15 AR ARP050105271A patent/AR055009A1/es unknown
- 2005-12-15 PE PE2005001474A patent/PE20060771A1/es not_active Application Discontinuation
- 2005-12-16 MY MYPI20055970A patent/MY143677A/en unknown
- 2005-12-19 TW TW094145118A patent/TWI326687B/zh not_active IP Right Cessation
-
2007
- 2007-06-04 ZA ZA200700501A patent/ZA200705019B/xx unknown
- 2007-06-04 IL IL183666A patent/IL183666A/en not_active IP Right Cessation
- 2007-06-29 NO NO20073368A patent/NO20073368L/no not_active Application Discontinuation
- 2007-07-13 MA MA30079A patent/MA29154B1/fr unknown
-
2008
- 2008-10-23 CY CY20081101194T patent/CY1108447T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055009A1 (es) | Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| CL2010001415A1 (es) | Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo | |
| GT200600445A (es) | Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo. | |
| CL2008001047A1 (es) | Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata. | |
| PA8785401A1 (es) | Derivados de bencimidazol | |
| CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
| CL2008002982A1 (es) | Compuestos derivados de 4,5-difenil-imidazol sustituidos por heterociclos, inhibidores mdm2; composicion farmaceutica que los comprende; proceso de preparacion de los compuestos; y uso en el tratamiento del cancer de mama, colon, pulmon o prostata. | |
| CL2007001435A1 (es) | Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer. | |
| DOP2011000218A (es) | Derivados de sulfonamida | |
| CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
| UY32237A (es) | Compuestos de arilo con sustituyentes heterociclicos y su uso | |
| CL2011000488A1 (es) | Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| AR077642A1 (es) | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| UA101393C2 (ru) | КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| AR056575A1 (es) | Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| SV2010003752A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |